Aktienanalyse zu Scinai Immunotherapeutics Ltd (SCNI)SCNIScinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Scinai Immunotherapeutics Ltd is not a good buy right now. The current price is $0.46, which is significantly down from its 52-week high of $13.00, indicating a drastic decline of 96.46%. The company has reported a staggering year-to-date change of -93.75% and a one-year change of -95.66%. Additionally, the RSI is at a very low level of 9.214, suggesting that the stock is oversold but may not rebound soon due to ongoing financial difficulties. The main risk is the company's negative net income of -$2,003,000 for Q2 2026, which raises concerns about its sustainability and future growth prospects.